David Greenway - Vertex Pharmaceuticals Director

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  Director
Mr. David Greenway is Director of the company. He has two decades of experience in managing, financing and developing growth strategies for various TSX Venture Exchangeand Canadian Securities Exchangelisted companies. His key expertise lies in the management and development of junior public resource companies, especially in the mining sector, and the oil and gas sector. He has held directorships, senior management and business development positions, including his role as the chief executive officer of Stamper Oil Gas Corporationration, Chief Consolidated Gold Mines and SNS Silver Corporationration, and his board position in Mountain View Conservation Centre.
Age: 34  Director Since 2017      
617 341-6100  www.vrtx.com

Management Efficiency

The company has return on total asset (ROA) of 8.3 % which means that it generated profit of $8.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 51.75 % meaning that it created $51.75 on every $100 dollars invested by stockholders.
The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Charles BakerRegeneron Pharmaceuticals
N/A
Willie ReedZoetis
2014
David BullockOrigin Agritech Limited
2015
Bruce CarterDr Reddys Laboratories Ltd
2008
Paul BisaroZoetis
2015
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
Bradley AlfordPerrigo Company Plc
2017
Ashok GangulyDr Reddys Laboratories Ltd
2009
Jeffrey KindlerPerrigo Company Plc
2017
Gary KunklePerrigo Company Plc
2009
Michael JandernoaPerrigo Company Plc
2007
Gary CohenPerrigo Company Plc
2009
Robert ScullyZoetis
2013
Gregory NordenZoetis
2013
Sanjay KhoslaZoetis
2013
William SteereZoetis
2013
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Prasad MenonDr Reddys Laboratories Ltd
2019
Sridar IyengarDr Reddys Laboratories Ltd
2011
Theodore SamuelstoPerrigo Company Plc
2017
Linda RhodesZoetis
2017

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased over 200 shares of
a day ago
Traded for 14.76
Purchased over 50 shares of
a day ago
Traded for 53.37
Purchased few shares of
a day ago
Traded for 270.71
Also please take a look at World Market Map. Please also try Portfolio Reporting module to create custom reports across your portfolios and generate quick suggestion pitch.
Search macroaxis.com